Acquisition provides assets targeting the tumor stroma and myeloid cells
These new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers and myeloid cell modulators
Acquisition of Versant-built company based in Toronto’s MaRS Discovery District
Share this: 
